Point72 Asset Management L.P. Acquires 2,210,708 Shares of Affimed (NASDAQ:AFMD)

Point72 Asset Management L.P. boosted its holdings in shares of Affimed (NASDAQ:AFMD) by 71.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,285,708 shares of the biopharmaceutical company’s stock after acquiring an additional 2,210,708 shares during the quarter. Point72 Asset Management L.P. owned 0.05% of Affimed worth $41,810,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of AFMD. D. E. Shaw & Co. Inc. boosted its stake in shares of Affimed by 39.1% in the 1st quarter. D. E. Shaw & Co. Inc. now owns 653,914 shares of the biopharmaceutical company’s stock valued at $5,173,000 after purchasing an additional 183,962 shares during the last quarter. Verition Fund Management LLC boosted its stake in shares of Affimed by 49.0% in the 1st quarter. Verition Fund Management LLC now owns 770,887 shares of the biopharmaceutical company’s stock valued at $6,098,000 after purchasing an additional 253,640 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Affimed by 31.1% in the 1st quarter. Jane Street Group LLC now owns 42,819 shares of the biopharmaceutical company’s stock valued at $339,000 after purchasing an additional 10,161 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Affimed by 32.4% in the 1st quarter. California State Teachers Retirement System now owns 170,200 shares of the biopharmaceutical company’s stock valued at $1,346,000 after purchasing an additional 41,612 shares during the last quarter. Finally, Silverarc Capital Management LLC boosted its stake in shares of Affimed by 25.6% in the 1st quarter. Silverarc Capital Management LLC now owns 502,330 shares of the biopharmaceutical company’s stock valued at $3,973,000 after purchasing an additional 102,330 shares during the last quarter. 79.63% of the stock is currently owned by hedge funds and other institutional investors.

AFMD stock opened at $6.84 on Thursday. The stock has a market capitalization of $672.30 million, a P/E ratio of -15.20 and a beta of 2.70. Affimed has a one year low of $3.07 and a one year high of $11.74. The business’s 50 day simple moving average is $8.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.93 and a quick ratio of 3.93.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings results on Wednesday, June 30th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.11. Affimed had a negative net margin of 88.48% and a negative return on equity of 37.87%. As a group, equities analysts forecast that Affimed will post -0.19 EPS for the current fiscal year.

Several research analysts recently issued reports on AFMD shares. BMO Capital Markets increased their target price on shares of Affimed from $12.00 to $15.00 and gave the stock an “outperform” rating in a research note on Monday, April 12th. Wells Fargo & Company upped their price objective on shares of Affimed from $10.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, March 24th. SVB Leerink restated a “buy” rating on shares of Affimed in a report on Sunday, April 18th. Credit Suisse Group assumed coverage on shares of Affimed in a research report on Tuesday, March 30th. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Zacks Investment Research raised shares of Affimed from a “sell” rating to a “hold” rating in a research note on Friday, July 2nd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $13.80.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL.

Featured Article: Market Capitalization – What it Means for Investors

Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed (NASDAQ:AFMD).

Institutional Ownership by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.